Revolution Medicines, Inc.

Good day and welcome to Revolution Medicine's first quarter 2023 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 1 on your telephone. You will then hear an automated message advising that your hand is raised. To withdraw your question, simply press star 1 1 again. Now, we ask that each participant limit their questions to one initial question and one follow-up question. After that, we just simply ask that you rejoin the queue, and we will address additional questions as time permits. As a reminder, today's conference is being recorded. I would now like to turn the conference over to your host, Aaron Graves, Senior Director of Corporate Communications and Investor Relations. Aaron, please go ahead.

Thank you and welcome everyone to the first quarter 2023 earnings call. Joining me on today's call are Dr. Mark Goldsmith, Revolution Medicine's chairman and chief executive officer, Dr. Steve Kelsey, our president of R&D, and Jack Anders, our chief financial officer. Peg Horn, our chief operating officer, will also join us for the Q&A portion of today's call. As we begin, I would like to note that our presentation will include statements regarding the current beliefs of the company with respect to our business that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act. These statements are subject to a number of assumptions, risks, and uncertainties. Actual results may differ materially from these statements, and except as required by law, the company undertakes no obligation to revise or update any forward-looking statements. I encourage you to review the legal disclaimer slide of our corporate presentation or the earnings press release, as well as all of the company filings with the SEC concerning these and other matters. During this call, we will be referring to a few slides from our corporate presentation, which was posted to our website prior to this call. With that, I will turn the call over to Dr. Mark Goldsmith, Revolution Medicine's Chairman and Chief Executive Officer. Mark.

Thanks, Erin. It's good to be with you this afternoon and to provide an update on our first quarter 2023 earnings. On today's call, I'll provide a brief update on our company progress. Dr. Kelsey will cover a few highlights of our R&D progress, and Jack Andrews will provide highlights of our financial results before we open the line for questions. We're off to a strong start this year with two important steps that we shared in the first quarter. First, we communicated early findings from the Phase 1-1B study of RMC6236, our first-in-class RAS multi-on inhibitor, which showed encouraging anti-tumor activity, safety, and tolerability for patients with advanced solid tumors harboring a range of distinct KRAS G12X mutations, particularly KRAS G12D and KRAS G12V. While covering a relatively small sample size, this was an important update as it provided initial validation of the novel mechanism of action and potential clinical utility of RMT6236 and also carried positive implications across our pioneering and deep portfolio of RAS on inhibitors. A second important step was a successful public equity offering in March, which raised $345 million of gross proceeds and further reinforced our strong financial position. The additional capital is allowing us to consider additional near-term and long-term investments to strengthen clinical development of our first wave of RAS-on inhibitors and to prepare our organization for the advancement of RMC6236 through the hiring of additional senior leaders and staff. We'll now turn to Dr. Steve Kelsey to review several clinical and preclinical highlights from the quarter. Steve?